Oncternal Therapeutics Inc (ONCT)
$9
+0.39
(+4.53%)▲
Insights on Oncternal Therapeutics Inc
Increasing Revenue
Revenue is up for the last 4 quarters, 106.0K → 569.0K (in $), with an average increase of 42.8% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -9.86M → -8.38M (in $), with an average increase of 8.4% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 58.5% return, outperforming this stock by 18.7%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 232.5% return, outperforming this stock by 324.3%
Performance
- $8.80$9.10$9.00
2.22%
Downside
Day's Volatility :3.3%
Upside
1.1%
- $5.57$13.14$9.00
38.11%
Downside
52 Weeks Volatility :57.61%
Upside
31.51%
Returns
| Period | Oncternal Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -6.41% | -0.6% | 0.0% |
6 Months | 32.46% | 12.1% | 0.0% |
1 Year | 39.82% | 11.3% | 0.0% |
3 Years | -91.75% | 17.6% | -20.1% |
Highlights
Market Capitalization | 25.5M |
Book Value | $10.19 |
Earnings Per Share (EPS) | -12.33 |
Wall Street Target Price | 27.67 |
Profit Margin | 0.0% |
Operating Margin TTM | -1542.88% |
Return On Assets TTM | -49.48% |
Return On Equity TTM | -86.75% |
Revenue TTM | 1.2M |
Revenue Per Share TTM | 0.39 |
Quarterly Revenue Growth YOY | 180.29999999999998% |
Gross Profit TTM | -31.5M |
Diluted Eps TTM | -12.33 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -11.77 |
EPS Estimate Next Year | -9.42 |
EPS Estimate Current Quarter | -2.88 |
EPS Estimate Next Quarter | -2.6 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 207.44%
Technicals Summary
Sell
Neutral
Buy
Oncternal Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Oncternal Therapeutics Inc | 0.7% | 32.46% | 39.82% | -91.75% | 735.92% |
 Moderna, Inc. | 37.56% | 83.82% | 13.37% | -12.47% | 553.14% |
 Regeneron Pharmaceuticals, Inc. | 10.42% | 24.29% | 32.26% | 98.6% | 210.52% |
 Novo Nordisk A/s | 7.9% | 30.89% | 58.53% | 230.87% | 458.51% |
 Vertex Pharmaceuticals Incorporated | 10.52% | 25.13% | 30.01% | 109.26% | 156.43% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Oncternal Therapeutics Inc | NA | NA | NA | -11.77 | -0.87 | -0.49 | NA | 10.19 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.46 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 29.16 | 29.16 | 1.46 | 44.2 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 45.83 | 45.83 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 28.9 | 28.9 | 0.53 | 17.11 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Oncternal Therapeutics Inc | Buy | $25.5M | 735.92% | NA | 0.0% |
Moderna, Inc. | Buy | $54.0B | 553.14% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.8B | 210.52% | 29.16 | 29.45% |
Novo Nordisk A/s | Buy | $592.1B | 458.51% | 45.83 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $115.1B | 156.43% | 28.9 | 39.46% |
Institutional Holdings
Vanguard Group Inc
4.83%Millennium Management LLC
3.48%BlackRock Inc
1.33%Dimensional Fund Advisors, Inc.
0.87%Richmond Brothers Inc
0.83%Renaissance Technologies Corp
0.55%
Corporate Announcements
Oncternal Therapeutics Inc Earnings
Oncternal Therapeutics Inc’s price-to-earnings ratio stands at None
Read More
Company Information
oncternal therapeutics, inc., a clinical-stage biopharmaceutical company, develops oncology therapies for the treatment of cancers with critical unmet medical need. the company's product pipeline include cirmtuzumab, a monoclonal antibody designed to inhibit the receptor-tyrosine kinase-like orphan receptor 1 (ror1) that is in phase i/ii clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia; and is in phase ib clinical trial in combination with paclitaxel for the treatment of women with human epidermal growth factor receptor 2-negative metastatic or breast cancer. it also develops tk-216, a small-molecule that is designed to inhibit e26 transformation specific family of oncoproteins, which is in phase i clinical trial to treat patients with ewing sarcoma and in combination with vincristine chemotherapy. in addition, the company develops a chimeric antigen receptor-t product candidate that targets ror1, whic
Organization | Oncternal Therapeutics Inc |
Employees | 27 |
CEO | Dr. James B. Breitmeyer M.D., Ph.D. |
Industry | Biotechnology |
Discover More
A Spac I Acquisition Corp
$9.00
+4.53%
Keyarch Acquisition Corp
$9.00
+4.53%
Connexa Sports Technologies Inc
$9.00
+4.53%
Us Value Etf
$9.00
+4.53%
First Wave Biopharma Inc
$9.00
+4.53%
Global X Msci Next Emerging
$9.00
+4.53%
Fat Projects Acquisition Corp
$9.00
+4.53%
Ishares Intl Div Growth Etf
$9.00
+4.53%
Corsair Gaming, Inc.
$9.00
+4.53%